Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
Ann-Marie E Bröske, Koorosh Korfi, Anton Belousov, Sabine Wilson, Chia-Huey Ooi, Christopher R Bolen, Marta Canamero, Enrique Gomez Alcaide, Ian James, Emily C Piccione, David J Carlile, Natalie Dimier, Pablo Umaña, Marina Bacac, Martin Weisser, Michael Dickinson, Ann-Marie E Bröske, Koorosh Korfi, Anton Belousov, Sabine Wilson, Chia-Huey Ooi, Christopher R Bolen, Marta Canamero, Enrique Gomez Alcaide, Ian James, Emily C Piccione, David J Carlile, Natalie Dimier, Pablo Umaña, Marina Bacac, Martin Weisser, Michael Dickinson
Abstract
Glofitamab, a novel CD20xCD3, T-cell-engaging bispecific antibody, exhibited single-agent activity in Study NP30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma. Preclinical studies showed that glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Here, we provide evidence of glofitamab's clinical activity, including pharmacodynamic profile, mode of action, and factors associated with clinical response, by evaluating biomarkers in patient samples from the dose-escalation part of this trial. Patients enrolled in Study NP30179 received single-dose obinutuzumab pretreatment (1000 mg) 7 days before IV glofitamab (5 µg-25 mg). Glofitamab treatment lasted ≤12 cycles once every 2 or 3 weeks. Blood samples were collected at predefined time points per the clinical protocol; T-cell populations were evaluated centrally by flow cytometry, and cytokine profiles were analyzed. Immunohistochemical and genomic biomarker analyses were performed on tumor biopsy samples. Pharmacodynamic modulation was observed with glofitamab treatment, including dose-dependent induction of cytokines, and T-cell margination, proliferation, and activation in peripheral blood. Gene expression analysis of pretreatment tumor biopsy samples indicated that tumor cell intrinsic factors such as TP53 signaling are associated with resistance to glofitamab, but they may also be interlinked with a diminished effector T-cell profile in resistant tumors and thus represent a poor prognostic factor per se. This integrative biomarker data analysis provides clinical evidence regarding glofitamab's mode of action, supports optimal biological dose selection, and will further guide clinical development. This trial was registered at www.clinicaltrials.gov as #NCT03075696.
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Figures
References
- Salles G, Barrett M, Foà R, et al. . Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232-2273.
- Hübel K, Ghielmini M, Ladetto M, Gopal AK. Controversies in the treatment of follicular lymphoma. HemaSphere. 2020;4(1):e317.
- Sehn LH, Berry B, Chhanabhai M, et al. . The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-1861.
- Galon J, Rossi J, Turcan S, et al. . Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19). J Clin Oncol. 2017;35(15):3025.
- Bacac M, Colombetti S, Herter S, et al. . CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018;24(19):4785-4797.
- Hutchings M, Morschhauser F, Iacoboni G, et al. . Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021;39(18):1959-1970.
- Liu S, Yin G, Yuan Y. Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. Ann Appl Stat. 2013; 7(4):1837-2457.
- Cheson BD, Fisher RI, Barrington SF, et al. ; United Kingdom National Cancer Research Institute . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
- bcl2fastq2 Conversion Software v2.20. Illumina; 2020. Available at: . Accessed 1 November 2020.
- Fast QC. A quality control tool for high throughput sequence data. Babraham Institute; 2019. Available at: . Accessed 1 November 2020.
- Dobin A, Davis CA, Schlesinger F, et al. . STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.
- Ewels P, Magnusson M, Lundin S, Käller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32(19):3047-3048.
- Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923-930.
- Bolen CR. GOYA DLBCL clinical trial–RNASeq dataset, geo, V1. 2019. Available at: . Accessed 1 November 2020.
- Frampton GM, Fichtenholtz A, Otto GA, et al. . Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023-1031.
- Zhang JD, Hatje K, Sturm G, et al. . Detect tissue heterogeneity in gene expression data with BioQC [published correction appears in BMC Genomics. 2018;19(1):558]. BMC Genomics. 2017;18(1):277.
- Mössner E, Brünker P, Moser S, et al. . Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-4402.
- Doering TA, Crawford A, Angelosanto JM, Paley MA, Ziegler CG, Wherry EJ. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity. 2012;37(6):1130-1144.
- Thommen DS, Koelzer VH, Herzig P, et al. . A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24(7):994-1004.
- Yu D, Cozma D, Park A, Thomas-Tikhonenko A. Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor. Ann N Y Acad Sci. 2005;1059(1):145-159.
- Scian MJ, Carchman EH, Mohanraj L, et al. . Wild-type p53 and p73 negatively regulate expression of proliferation related genes. Oncogene. 2008;27(18):2583-2593.
- Blagih J, Buck MD, Vousden KH. p53, cancer and the immune response. J Cell Sci. 2020;133(5):jcs237453.
- Araf S, Korfi K, Bewicke-Copley F, et al. . Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. Haematologica. 2020;105(6):318-321.
- Wang XJ, Medeiros LJ, Bueso-Ramos CE, et al. . P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. Mod Pathol. 2017;30(2):194-203.
- Zenz T, Kreuz M, Fuge M, et al. ; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) . TP53 mutation and survival in aggressive B cell lymphoma. Int J Cancer. 2017;141(7):1381-1388.
- Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013;122(24):3884-3891.
- Cook D, Brown D, Alexander R, et al. . Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419-431.
- Coyle L, Morley NJ, Rambaldi A, et al. . Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2020;61(9):2103-2112.
- Costa L, Wong SW, Bermúdez A, et al. . First clinical study of the B-cell maturation antigen (BCMA) 2 + 1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. 2019;134(suppl 1):143.
- Oya Y, Yoshida T, Kuroda H, et al. . Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. Oncotarget. 2017;8(61):103117-103128.
- Schalper KA, Carleton M, Zhou M, et al. . Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020;26(5):688-692.
- Riedl JM, Barth DA, Brueckl WM, et al. . C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: a bi-center study. Cancers (Basel). 2020;12(8):2319.
- Yuen KC, Liu LF, Gupta V, et al. . High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade [published correction appears in Nat Med. 2021;27(3):560]. Nat Med. 2020;26(5):693-698.
- Yoshida T, Ichikawa J, Giuroiu I, et al. . C reactive protein impairs adaptive immunity in immune cells of patients with melanoma [published correction appears in J Immunother Cancer. 2020;8(1):e000234corr1]. J Immunother Cancer. 2020;8(1):e000234.
- Cheng J, Zhao L, Zhang Y, et al. . Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies. Front Oncol. 2019;9:1237.
- Cremasco F, Menietti E, Speziale D, et al. . Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model. PLoS One. 2021;16(1):e0241091.
- Sanmamed MF, Nie X, Desai SS, et al. . A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy. Cancer Discov. 2021;11(7):1700-1715.
- Pascual M, Mena-Varas M, Robles EF, et al. . PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood. 2019;133(22):2401-2412.
- Ghosh M, Saha S, Bettke J, et al. . Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell. 2021;39(4): 494-508.e5.
- Kotlov N, Bagaev A, Revuelta MV, et al. . Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov. 2021;11(6):1468-1489.
Source: PubMed